Hematologic Cancer News and Features

Pomalidomide Plus Dexamethasone Effective in R/R Multiple Myeloma

Pomalidomide Plus Dexamethasone Effective in R/R Multiple Myeloma

Researchers report on their findings of a retrospective study that compared pomalidomide plus dexamethasone vs dexamethasone alone in patients with relapsed/refractory multiple myeloma.

ITP Treatment Outcomes Not Improved With Intravenous vs Oral Corticosteroids

ITP Treatment Outcomes Not Improved With Intravenous vs Oral Corticosteroids

In this prospective study, researchers sought to compare the effectiveness of IV methylprednisolone vs oral prednisone in hospitalized patients with newly diagnosed ITP.

Shorter overall survival among patients with monoclonal gammopathy of undetermined significance

1. Patients diagnosed with monoclonal gammopathy of undetermined significance (MGUS) and followed for multiple decades showed shorter overall survival rates compared to matched controls. 2. Risk of progression to multiple myeloma or another blood cell disorder was associated with identified adverse risk factors. Evidence Rating: 1 (Excellent) Study Rundown: MGUS is a relatively common condition []

Fosfomycin Effective Alternate for Febrile Neutropenia Prophylaxis

Fosfomycin Effective Alternate for Febrile Neutropenia Prophylaxis

A retrospective chart study demonstrated the effectiveness of fosfomycin as an antibacterial prophylaxis for febrile neutropenia in patients with hematologic cancer.

Breast Implants Associated With Increased Risk of Breast Anaplastic Large-cell Lymphoma

Breast Implants Associated With Increased Risk of Breast Anaplastic Large-cell Lymphoma

The safety of breast implants has not been confirmed despite widespread use.

High-Dose Dexamethasone Effective With Less Adverse Effects in ITP vs Corticosteroids

High-Dose Dexamethasone Effective With Less Adverse Effects in ITP vs Corticosteroids

In this randomized trial, investigators sought to determine the effectiveness of high-dose dexamethasone vs conventional prednisone therapy in treatment-naïve patients with ITP. Results were presented at ASH 2017.

Aspirin Does Not Reduce Risk of Venous Thromboembolism in Multiple Myeloma

Aspirin Does Not Reduce Risk of Venous Thromboembolism in Multiple Myeloma

A retrospective study, presented at ASH 2017, determined the effectiveness of aspirin in reducing risk of VTE in patients with multiple myeloma at high risk of developing VTE.

Leukocytosis

Ruxolitinib Beneficial in Hydroxyurea Resistant/Intolerant Polycythemia Vera

Ruxolitinib Beneficial in Hydroxyurea Resistant/Intolerant Polycythemia Vera

Data presented at ASH 2017 confirm that ruxolitinib improves hematocrit control, hematologic remission, and reduction in spleen size in some patients with polycythemia vera who fail hydroxyurea.

Ibrutinib Effective As First-line Therapy in Waldenström's Macroglobulinemia

Ibrutinib Effective As First-line Therapy in Waldenström's Macroglobulinemia

Ibrutinib — a Bruton tyrosine kinase inhibitor — is currently used among patients with WM who have previously received treatment. This prospective, phase 2 study sought to determine its efficacy as a first-line therapy in treatment-naive patients.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs